Dinesh Pal Mudaranthakam, PhD, MBA, MS

Professional Background

As a health policy and economic researcher, I focus on evaluating the cost-effectiveness and economic burden of cancer and Alzheimer’s care to inform resource allocation and improve patient outcomes. My work integrates real-world data, longitudinal analyses, and predictive modeling to design and assess high-value interventions that reduce financial and access barriers while maximizing clinical impact. By leveraging advanced analytics, machine learning, and AI, I translate complex data into decision-support tools that guide policy, reimbursement strategies, and scalable implementation across health systems.

I lead the development of research data infrastructure, including enterprise data warehouses such as the Cancer Curated Clinical Outcomes Database (C3OD), to support clinical trial feasibility, recruitment, and outcomes evaluation. With over 15 years of experience in multi-site clinical research systems, I design and implement compliant, scalable platforms that enable rigorous economic and outcomes research, from data acquisition through dissemination. My work bridges informatics and economic evaluation to generate actionable evidence for value-based care and policy translation in oncology and aging populations.

• PhD, Health Policy & Management, University of Kansas Medical Center, Kansas City, Ks
• MBA, Leadership and Manangement, University of Kansas, Lawrance, Kansas
• MS, Computer Science, Kansas State University, Manhattan, Kansas
• Other, Computer Science, Jawaharlal Nehru Technology University, Hyderabad, Telengana

• Tableau, Tableau

• Rural Health Center- Data and Informatics Committee, Data and Informatics Committee, Chair, 2023 - Present
• AcademyHealth, Member, 2021 - Present
• American Statistical Association (ASA), Member, 2021 - Present

Research

Overview

Research interests: Health Economic and Outcome Research, Population health, epidemiology, electronic health records, administrative claims data, observational study design, categorical data analysis, survival analysis, longitudinal data, System integration, Informatics Eco-system

Current research areas include Financial Toxicity among Cancer Patients, Rural/Racial disparities, Informatics System integration, Clinical trial optimization. Our team has built an Informatics Eco-System combined with constructed in-house and 3rd party owned tools. Each system within the ecosystem helps expedite the research process and facilities that an individual research team performs on an extensive scheme of things. The crucial element has been integrated to avoid data discrepancy and the elimination of double data entry.

• Mudaranthakam DP, Nollen N, Wick J, Hughes D, Welch D, Calhoun E. 2023. Evaluating Work Impairment as a Source of Financial Toxicity in Cancer Healthcare and Negative Impacts on Health Status.. Cancer research communications, 3 (7), 1166-1172. https://aacrjournals.org/cancerrescommun/article/3/7/1166/727593/Evaluating-Work-Impairment-as-a-Source-of
• Mudaranthakam DP, Hughes D, Johnson P, Mason T, Nollen N, Wick J, Welch DR, Calhoun E. 2023. Career disruption and limitation of financial earnings due to cancer.. JNCI cancer spectrum. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10359624/
• Mudaranthakam DP, Thompson J, Hu J, Pei D, Chintala SR, Park M, Fridley BL, Gajewski B, Koestler DC, Mayo MS. 2018. A Curated Cancer Clinical Outcomes Database (C3OD) for accelerating patient recruitment in cancer clinical trials.. JAMIA open, 1 (2), 166-171. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6241508/
• Mudaranthakam DineshPal, Phadnis MilindA., Krebill Ron, Clark Lauren, Wick JoA., Thompson Jeffrey, Keighley John, Gajewski ByronJ., Koestler DevinC., Mayo MatthewS.. 2020. Improving the efficiency of clinical trials by standardizing processes for Investigator Initiated Trials. CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 18. https://www.clinicalkey.com/#!/content/playContent/1-s2.0-S2451865420300636?returnurl=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS2451865420300636%3Fshowall%3Dtrue&referrer=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F
• Mudaranthakam DineshPal, Harlan-Williams LisaM., Jensen RoyA., Kuo Hanluen, Garimella Vandita, Chen RonaldC., Mayo MatthewS., Krebill Hope. 2020. OPTIK: a database for understanding catchment areas to guide mobilization of cancer center assets. DATABASE-THE JOURNAL OF BIOLOGICAL DATABASES AND CURATION. https://academic.oup.com/database/article/doi/10.1093/database/baaa054/5876850?login=true
• Mudaranthakam DineshPal, Cernik Colin, Curtis Leslie, Griffith Blake, Hu Jinxiang, Wick Jo, Thompson Jeffrey, Gajewski Byron, Koestler Devin, Jensen RoyA., Mayo MatthewS.. 2020. Utilization of Technology to Improve Efficiency in Investigational Drug Management Processes. JOURNAL OF PHARMACY TECHNOLOGY, 36 (2), 84-90
• Fabian CJ, Mudaranthakam DP. 2023. Reduced-Frequency Endocrine Therapy and Challenges of Noninferiority Study Designs.. JAMA oncology. https://jamanetwork.com/journals/jamaoncology/fullarticle/2802830
• Ratnaparkhi R, Ismail A, Krebill H, Cook I, Javellana M, Jewell A, Spoozak L, Emerson A, Ramaswamy M, Calhoun E, Mudaranthakam DP. 2024. Utilization and outcomes of serial cervical cancer screening in a National Breast and Cervical Cancer Early Detection Program (NBCCEDP) in a non-Medicaid expansion state.. Cancer causes & control : CCC
• Barohn RJ, Gajewski B, Pasnoor M, Brown A, Herbelin LL, Kimminau KS, Mudaranthakam DP, Jawdat O, Dimachkie MM, Iyadurai S, Stino A, Kissel J, Pascuzzi R, Brannagan T, Wicklund M, Ahmed A, Walk D, Smith G, Quan D, Heitzman D, Tobon A, Ladha S, Wolfe G, Pulley M, Hayat G, Li Y, Thaisetthawatkul P, Lewis R, Biliciler S, Sharma K, Salajegheh K, Trivedi J, Mallonee W, Burns T, Jacoby M, Bril V, Vu T, Ramchandren S, Bazant M, Austin S, Karam C, Hussain Y, Kutz C, Twydell P, Scelsa S, Kushlaf H, Wymer J, Hehir M, Kolb N, Ralph J, Barboi A, Verma N, Ahmed M, Memon A, Saperstein D, Lou JS, Swenson A, Cash T. 2021. Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations (PAIN-CONTRoLS): Bayesian Adaptive Comparative Effectiveness Randomized Trial.. JAMA neurology, 78 (1), 68-76. https://jamanetwork.com/journals/jamaneurology/fullarticle/2769608
• Sharma P, Kimler BF, O'Dea A, Nye L, Wang YY, Yoder R, Staley JM, Prochaska L, Wagner J, Amin AL, Larson K, Balanoff C, Elia M, Crane G, Madhusudhana S, Hoffmann M, Sheehan M, Rodriguez R, Finke K, Shah R, Satelli D, Shrestha A, Beck L, McKittrick R, Pluenneke R, Raja V, Beeki V, Corum L, Heldstab J, LaFaver S, Prager M, Phadnis M, Mudaranthakam DP, Jensen RA, Godwin AK, Salgado R, Mehta K, Khan Q. 2021. Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I-III Triple-negative Breast Cancer (NeoSTOP).. Clinical cancer research : an official journal of the American Association for Cancer Research, 27 (4), 975-982. https://aacrjournals.org/clincancerres/article/27/4/975/125183/Randomized-Phase-II-Trial-of-Anthracycline-free